MedPath

Vertical Soft Tissue Augmentation With CTG vs ADM

Not Applicable
Recruiting
Conditions
Implant Complication
Interventions
Procedure: Vertical soft tissue augmentation
Registration Number
NCT05729607
Lead Sponsor
Harvard Medical School (HMS and HSDM)
Brief Summary

The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative

Detailed Description

The present randomized clinical trial aims at investigating two approaches (autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative) when performed for vertical soft tissue augmentation at sites with peri-implant soft tissue dehiscences. Clinical, volumetric, ultrasonographic, and patient-reported outcomes will be evaluated at different time points up to 1 year.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
28
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dermal matrix + EMDVertical soft tissue augmentationAcellular dermal matrix and enamel matrix derivative
Connective tissue graftVertical soft tissue augmentationAutogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized
Primary Outcome Measures
NameTimeMethod
Change in Soft tissue dehiscence depth12 months

Change of the depth of the Soft tissue dehiscence (vertical measurement of the complication, in relation to the level of the cemento-enamel junction of the contralateral homologous tooth) at 12 months compared to baseline (expressed in millimeters)

Secondary Outcome Measures
NameTimeMethod
Mucosal thickness changes3, 6, and 12 months

Changes within the mucosal thickness measured with ultrasonography (expressed in mm)

Professional esthetic assessment (IDES)12 months

Esthetic outcomes of the treatment assessed by a calibrated operator using the Implant soft tissue Dehiscence coverage Esthetic Score (IDES) (expressed using points, based on the IDES classification system from Zucchelli et al. 2021) The range is from 0 (worst outcome) to 10 (best outcome)

3D Volumetric changes3, 6, and 12 months

Changes within the buccal contour measured by superimposing digital impressions obtained with optical scanning (expressed in mm\^3)

Complete peri-implant soft tissue dehiscence (PSTD) coverage12 months

Percentage of cases with complete resolution of the implant esthetic complication (expressed as a percentage)

mean peri-implant soft tissue dehiscence (PSTD) coverage12 months

Percentage of coverage of the soft tissue dehiscence compared to baseline, measured with a formula considering final PSTD depth and initial PSTD depth (expressed as a percentage)

Post-operative pain14 days after the surgery

Patient-reported pain after the surgical procedure (expressed with a 0-10 visual analogue scale \[VAS\])

Trial Locations

Locations (1)

Harvard School of Dental Medicine

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath